Premium
Impaired production of interferon‐α in whole‐blood cultures from patients with renal cell carcinoma
Author(s) -
Kuo J.Y.,
Kita M.,
Imanishi J.,
Yoshida O.
Publication year - 1996
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1046/j.1464-410x.1996.08426.x
Subject(s) - renal cell carcinoma , medicine , stage (stratigraphy) , gastroenterology , interferon , whole blood , immune system , immunology , biology , paleontology
Objective To determine the immune status of patients with renal cell carcinoma (RCC) by estimating the production of interferon‐α (IFN‐α) in whole‐blood cultures from these patients and from healthy subjects. Patients, subjects and methods Peripheral blood (2 mL) was collected from 30 untreated patients (23 men and seven women, mean age 59 years, range 35–78) with RCC and 30 healthy subjects (23 men and seven women, mean age 62 years). The patients with RCC comprised 17 with low‐stage (stage I, II) and 13 patients with high‐stage (stage III, IV) RCC. Sendai virus was added to the samples and incubated at 37°C for 20 h, the supernatants collected and the activity of IFN‐α determined by a conventional cytopathic‐effect inhibition assay performed in microtitre plates with FL cells and challenged with vesicular stomatitis virus. Results The production of IFN‐α was suppressed significantly in patients with high‐stage RCC compared with that in the control subjects ( P <0.05), but there was no significant difference when compared to patients with low‐stage RCC. Conclusion This study demonstrated that the immune status of patients with high‐stage RCC was impaired significantly and exogenous IFN‐α therapy might be beneficial clinically for this group.